Bundle mii-exa-befund-bundle-befund-fgfr2-fusion of type transaction

Entry 1 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-patient-fgfr2-fusion

Resource Patient:

Language: en

Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

---

Deceased:	false
Contact Detail	10 DE

Request:

PUT Patient/mii-exa-molgen-patient-fgfr2-fusion

Entry 2 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-practitioner-lab

Resource Practitioner:

Language: en

active: true

name: Dr. Daniel Schmidt(Official)

Request:

PUT Practitioner/mii-exa-molgen-practitioner-lab

Entry 3 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-practitioner-physician

Resource Practitioner:

Language: en

active: true

name: Dr. Linda Rubens(Official)

Request:

PUT Practitioner/mii-exa-molgen-practitioner-physician

Entry 4 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-befundbericht-fgfr2-fusion

Resource DiagnosticReport:

Language: en

Profiles: MII PR MolGen Molekulargenetischer Befundbericht version: 2027.0.0-ballot.1, Genomic Report version: 3.0.0

Genetic analysis report (Genetics)

Subject	Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))
Performer	Practitioner Dr. Daniel Schmidt(official)

Report Details

Code	Value	Flags	Relevant Time
Diagnostic Implication		Final	2022-11-30
Genetic variant assessment	Present	Final	2022-11-30
Therapeutic Implication		Final	2022-11-30

Nachweis FGFR2-Fusion. Empfehlung: Hochselektive FGFR-Inhibitor-Therapie.

Request:

PUT DiagnosticReport/mii-exa-molgen-befundbericht-fgfr2-fusion

Entry 5 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-anforderung-fgfr2-fusion

Resource ServiceRequest:

Language: en

Profile: MII PR MolGen Anforderung genetischer Test version: 2027.0.0-ballot.1

identifier: https://www.charite.de/fhir/auftragsnummern/PRK4QE59A

status: Active

intent: Order

category: Laboratory procedure (procedure)

code: No display for ServiceRequest.code (concept: Molecular genetic test (procedure))

subject: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

authoredOn: 2022-11-30

requester: Practitioner Dr. Linda Rubens(official)

Request:

PUT ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion

Entry 6 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-variante-fgfr2-fusion

Resource Observation:

Language: en

Profiles: MII PR MolGen Variante version: 2027.0.0-ballot.1, Variant version: 3.0.0

basedOn: ServiceRequest Molecular genetic test (procedure)

status: Final

category: Laboratory, Genetics

code: Genetic variant assessment

subject: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

effective: 2022-11-30

value: Present

method: Sequencing

component

code: Gene studied [ID]

value: FGFR2

component

code: DNA change type

value: gene_fusion

component

code: Gene fusion transcript details in Blood or Tissue by Molecular genetics method Narrative

value: FGFR2::DBP

Request:

PUT Observation/mii-exa-molgen-variante-fgfr2-fusion

Entry 7 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-diagnostische-implikation-fgfr2-fusion

Resource Observation:

Language: en

Profiles: MII PR MolGen Diagnostische Implikation version: 2027.0.0-ballot.1, Diagnostic Implication version: 3.0.0

status: Final

category: Laboratory, Genetics

code: Diagnostic Implication

subject: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

effective: 2022-11-30

performer: Practitioner Dr. Daniel Schmidt(official)

derivedFrom: Observation Genetic variant assessment

Components

-	Code	Value[x]
*	Conclusion Text	starke Überexpression (25-fach)

Request:

PUT Observation/mii-exa-molgen-diagnostische-implikation-fgfr2-fusion

Entry 8 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion

Resource Observation:

Language: en

Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0

status: Final

category: Laboratory, Genetics

code: Therapeutic Implication

subject: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

effective: 2022-11-30

performer: Practitioner Dr. Daniel Schmidt(official)

derivedFrom: Observation Genetic variant assessment

component

code: Conclusion Text

value: Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie.

component

code: Medication assessed [ID]

value: Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren

component

code: Level of evidence

value: m1c

component

code: Associated phenotype

value: Intrahepatic bile duct carcinoma (disorder)

Request:

PUT Observation/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion

Entry 9 - fullUrl = https://www.medizininformatik-initiative.de/fhir/mii-exa-molgen-medikationsempfehlung-fgfr2-fusion

Resource Task:

Language: en

Profiles: MII PR MolGen Medikationsempfehlung version: 2027.0.0-ballot.1, Medication Recommendation version: 3.0.0

basedOn: ServiceRequest Molecular genetic test (procedure)

status: Requested

intent: Proposal

code: Hochselektive FGFR-Inhibitor-Therapie

for: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

Request:

PUT Task/mii-exa-molgen-medikationsempfehlung-fgfr2-fusion